Spyre Therapeutics (SYRE) Earnings Date & Reports
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases... Show more
SYRE is expected to report earnings to fall 1.15% to -73 cents per share on August 06
Spyre Therapeutics (SYRE) Q4 2025 Earnings Recap: Cash Runway Powers Pipeline Progress
Key Takeaways
- Spyre Therapeutics reported a Q4 2025 net loss of $62.5 million, compared to $56.3 million in the prior-year quarter, driven by increased general and administrative (G&A) expenses.
- Research and development (R&D) expenses decreased to $44.6 million in Q4 from $50.5 million year-over-year, while full-year R&D rose to $171.7 million reflecting pipeline investments.
- The company ended 2025 with $756.5 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028.
- No revenue was recorded, consistent with its clinical-stage biotechnology focus on immunology therapies.
- Key pipeline updates include Phase 2 SKYLINE trial readouts for ulcerative colitis (UC) in Q2 2026 and SKYWAY trial data for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) in Q4 2026.
- Shares surged approximately 14% on the earnings release day, signaling positive investor reception.
Earnings Context and Why It Matters
Spyre Therapeutics, a clinical-stage biotech developing next-generation therapies for inflammatory bowel disease (IBD) and other immune-mediated diseases, released its Q4 and full-year 2025 results amid heightened investor focus on its pipeline progress and financial health. With no commercial products yet, earnings emphasize cash position, burn rate, and clinical milestones—critical for sustaining multi-year development. The report follows a transformative 2025, including pipeline advancements and a $316 million financing in October, positioning Spyre to deliver multiple Phase 2 readouts in 2026. For investors, these results gauge the company's ability to execute amid biotech sector volatility and funding challenges.
Spyre reported a net loss of $62.5 million for Q4 2025, or approximately -$0.70 per share, compared to $56.3 million in Q4 2024. This compared to analyst expectations of around -$0.74 per share, marking a slight beat in some estimates. Full-year net loss narrowed to $155.2 million from $208.0 million in 2024, aided by a $10 million gain on an in-process R&D asset sale.
R&D expenses totaled $44.6 million in the quarter, down year-over-year due to optimized spending, though full-year investment increased to $171.7 million to support SPY001, SPY002, SPY003, and other programs. G&A rose to $12.5 million in Q4 from $10.8 million, with full-year at $47.9 million. No revenue was generated, aligning with pre-commercial status. Balance sheet strength shone with $756.5 million in cash and marketable securities at year-end.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Shares of Spyre Therapeutics jumped about 14% on February 19, 2026, the day of the earnings release, reflecting optimism over the extended cash runway and upcoming clinical catalysts. Investor sentiment remains bullish, bolstered by the company's pipeline momentum and a recent $463.5 million stock offering closed on April 16, 2026, which further fortifies its balance sheet. Trading volume spiked, underscoring focus on biotech innovators advancing immunology therapies.
Forward Outlook and Key Factors to Monitor
Following Q4 results, Spyre's priorities center on clinical execution. Investors should watch Part A topline data from the Phase 2 SKYLINE trial of SPY001 in UC, slated for Q2 2026, as it could validate the company's gut-selective immunology approach.
Later in 2026, four sub-studies from the SKYWAY Phase 2 basket trial (RA, PsA, axSpA, and non-radiographic axSpA) are expected in Q4, alongside additional proof-of-concept readouts. These milestones will test SPY001 and SPY002's potential in broader autoimmune indications.
Cash burn trends merit attention, with net operating cash use at $44.6 million in Q4. The $756.5 million position, plus recent financing, supports operations through H2 2028, but R&D ramp-up could influence trajectory. Upcoming Q1 2026 earnings in May will provide interim updates. Broader factors include biotech M&A (mergers and acquisitions) activity and inflammatory disease treatment dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology